{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:58:46Z","timestamp":1754481526265,"version":"3.30.1"},"reference-count":44,"publisher":"Medknow","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Res Pharm Pract"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/jrpp.jrpp_17_46","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T04:57:01Z","timestamp":1505969821000},"page":"135","source":"Crossref","is-referenced-by-count":3,"title":["Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis"],"prefix":"10.4103","volume":"6","author":[{"given":"Shekoufeh","family":"Nikfar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pardis","family":"Zaboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilan","family":"Mozaffari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2581","reference":[{"key":"key-10.4103\/2279-042X.215237-1","doi-asserted-by":"crossref","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42.","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"key-10.4103\/2279-042X.215237-2","first-page":"351","volume-title":"Have biologics changed the natural history of Crohn's disease?","author":"Mandel","year":"2014","journal-title":"Dig Dis"},{"key":"key-10.4103\/2279-042X.215237-3","first-page":"714","volume-title":"Asystematic review assessing medical treatment for rectovaginal and enterovesical fistulae in Crohn's disease","author":"Kaimakliotis","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"key-10.4103\/2279-042X.215237-4","doi-asserted-by":"crossref","unstructured":"Beck DE, Roberts PL, Saclarides TJ, Vasilevsky C, Gordon PH, Hoexter B, et al. Anorectal abscess and fistula. The ASCRS Textbook of Colon and Rectal Surgery. Ch. 13. New York: Springer; 2011.","DOI":"10.1007\/978-1-4419-1584-9"},{"key":"key-10.4103\/2279-042X.215237-5","first-page":"326","volume-title":"Experience with anti-TNF-\u03b1 biologic agents in succession in patients with Crohn's disease: A retrospective analysis of a single center","author":"Ferges","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"key-10.4103\/2279-042X.215237-6","doi-asserted-by":"crossref","unstructured":"Carter MJ, Lobo AJ, Travis SP. Guidelines for the treatment of inflammatory bowel disease in adults. Gut 2004;53.","DOI":"10.1136\/gut.2004.043372"},{"key":"key-10.4103\/2279-042X.215237-7","doi-asserted-by":"crossref","unstructured":"Sneider EB, Maykel JA. Anal abscess and fistula. Gastroenterol Clin N Am 2013. [Doi 10.1016\/j.gtc. 2013.08.003].","DOI":"10.1016\/j.gtc.2013.08.003"},{"key":"key-10.4103\/2279-042X.215237-8","first-page":"875","volume-title":", Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, et al. The natural history of Fistulizing Crohn's disease in Olmsted County, Minnesota","author":"Schwartz","year":"2002","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.215237-9","first-page":"577","volume-title":"Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in Fistulizing anorectal Crohn's disease: A single center experience","author":"Topstad","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"key-10.4103\/2279-042X.215237-10","first-page":"299","volume-title":"Treatment of complex perianal fistulas in Crohn disease: Infliximab, surgery or combined approach","author":"Sciaudone","year":"2010","journal-title":"Can J Surg"},{"key":"key-10.4103\/2279-042X.215237-11","first-page":"587","volume-title":"Seton treatment of complex anorectal fistulas in patients with Crohn's disease","author":"White","year":"1990","journal-title":"Dis Colon Rectum"},{"key":"key-10.4103\/2279-042X.215237-12","doi-asserted-by":"crossref","unstructured":"Wolff BG, Culp CE, Beart RW Jr., iLstrup DM, Roger MS, Ready L. Anorectal Crohn's disease. A long-term perspective. Dis Colon Rectum 1985;28:709-11.","DOI":"10.1007\/BF02560279"},{"key":"key-10.4103\/2279-042X.215237-13","first-page":"133","volume-title":"Surgical treatment of anorectal fistula in patients with Crohn's disease","author":"Levien","year":"1989","journal-title":"Surg Gynecol Obstet"},{"key":"key-10.4103\/2279-042X.215237-14","first-page":"378","volume-title":"Fistula-in-ano in Crohn's disease.Results of aggressive surgical treatment","author":"Williams","year":"1991","journal-title":"Dis Colon Rectum"},{"key":"key-10.4103\/2279-042X.215237-15","first-page":"1541","volume-title":"Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"key-10.4103\/2279-042X.215237-16","first-page":"907","volume-title":"Efficacy and safety of adalimumab for the Crohn's disease: A systematic review and meta-analysis of published randomized placebo-controlled trials","author":"Song","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.4103\/2279-042X.215237-17","first-page":"876","volume-title":"Infliximab maintenance therapy for Fistulizing Crohn's disease","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.215237-18","first-page":"323","volume-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.215237-19","first-page":"1493","volume-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.215237-20","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. Gastroenterology 2012;142:1102-11.e2.","DOI":"10.1053\/j.gastro.2012.01.035"},{"key":"key-10.4103\/2279-042X.215237-21","first-page":"228","volume-title":"Certolizumab pegol for the treatment of Crohn's disease","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.215237-22","first-page":"239","volume-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.215237-23","first-page":"103","volume-title":"Emerging issues in the medical treatment of Crohn's disease","author":"Targownik","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"key":"key-10.4103\/2279-042X.215237-24","first-page":"1029","volume-title":"Ashort-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.Crohn's disease cA2 study group","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.215237-25","first-page":"600","volume-title":"Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months","author":"Lichtenstein","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.4103\/2279-042X.215237-26","first-page":"1","volume-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"key-10.4103\/2279-042X.215237-27","first-page":"1","volume-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"key-10.4103\/2279-042X.215237-28","first-page":"185","volume-title":"Randomised clinical trial: Certolizumab pegol for fistulas in Crohn's disease-Subgroup results from a placebo-controlled study","author":"Schreiber","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/2279-042X.215237-29","first-page":"1330","volume-title":"An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.215237-30","first-page":"1485","volume-title":"CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: A randomised, double blind, placebo controlled trial","author":"Sandborn","year":"2004","journal-title":"Gut"},{"key":"key-10.4103\/2279-042X.215237-31","first-page":"765","volume-title":"Tumor necrosis factor-\u03b1 antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: Systematic review and meta-analysis","author":"Kawalec","year":"2013","journal-title":"Arch Med Sci"},{"key":"key-10.4103\/2279-042X.215237-32","first-page":"1088","volume-title":"Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.215237-33","first-page":"52","volume-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.215237-34","first-page":"829","volume-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/2279-042X.215237-35","first-page":"1398","volume-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.215237-36","first-page":"644","volume-title":"Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key-10.4103\/2279-042X.215237-37","first-page":"165","volume-title":"Efficacy and safety of adalimumab in Crohn's disease: Meta-analysis of placebo-controlled trials","author":"Huang","year":"2011","journal-title":"J Dig Dis"},{"key":"key-10.4103\/2279-042X.215237-38","first-page":"912","volume-title":"Long-term treatment of rectovaginal fistulas in Crohn's disease: Response to infliximab in the ACCENT II study","author":"Sands","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.4103\/2279-042X.215237-39","first-page":"940","volume-title":"Adalimumab for the treatment of fistulas in patients with Crohn's disease","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"key-10.4103\/2279-042X.215237-40","first-page":"1127","volume-title":"Maintenance infliximab does not result in increased abscess development in Fistulizing Crohn's disease: Results from the ACCENT II study","author":"Sands","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/2279-042X.215237-41","first-page":"644","volume-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.4103\/2279-042X.215237-42","first-page":"447","volume-title":"Systematic review with meta-analysis: Malignancies with anti-tumour necrosis factor-\u03b1 therapy in inflammatory bowel disease","author":"Williams","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/2279-042X.215237-43","first-page":"741","volume-title":"Systematic review: The combined surgical and medical treatment of fistulising perianal Crohn's disease","author":"Yassin","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/2279-042X.215237-44","first-page":"667","volume-title":"Treatment of perianal fistula in Crohn's disease: A systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment","author":"de","year":"2016","journal-title":"Colorectal Dis"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T19:45:15Z","timestamp":1570131915000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrpp.net\/text.asp?2017\/6\/3\/135\/215237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["215237"],"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_17_46","relation":{},"ISSN":["2279-042X"],"issn-type":[{"type":"print","value":"2279-042X"}],"subject":[],"published":{"date-parts":[[2017]]}}}